Abata Therapeutics
Robyn Hamel has extensive experience as an Executive Assistant across various organizations, currently serving at Abata Therapeutics since July 2023. Prior roles include positions at Ipsen, Sigilon Therapeutics, and Bioverativ, where responsibilities included assisting high-level executives. Early career experiences span roles at Bain Capital, Beth Israel Deaconess Medical Center, Consumer Marketing Solutions, and Hachette Book Group USA, where Robyn contributed to operations and program administration. Robyn is an alumnus of the University of Massachusetts Amherst.
Abata Therapeutics
1 followers
Abata Therapeutics is bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to their lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). They bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers.